☆ 4.6 Article

Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses

JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

DrugMAP: molecular atlas and pharma-information of all drugs

Fengcheng Li et al.

Summary: The efficacy and safety of drugs depend on their interactions with various pharmacologically important molecules. To better understand this information, a new database called DrugMAP has been developed, which provides a comprehensive list of interacting molecules for over 30,000 drugs/drug candidates. It also includes differential expression patterns for over 5,000 interacting molecules in different disease sites, ADME-relevant organs, and physiological tissues. With over 200,000 interactions among drugs and molecules, DrugMAP is expected to be a valuable resource for drug discovery and network analysis.

NUCLEIC ACIDS RESEARCH (2023)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Editorial overview: An initiative toward Ebolavirus disease (EVD) free world: An edited special anti-infective issue on Ebola virus disease

Elijah I. Ohimain et al.

CURRENT OPINION IN PHARMACOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs)

Aleksandr Ianevski et al.

Summary: Viruses can cause outbreaks in humans and have economic and health burdens. Broad-spectrum antivirals (BSAs) and BSA-containing drug combinations (BCCs) are immediate therapeutic options for virus identification and vaccine development. DrugVirus.info 2.0 provides an integrative portal for exploration and analysis of BSAs and BCCs, expanding the database and functionality for antiviral drug development.

NUCLEIC ACIDS RESEARCH (2022)

Add to Collection

Review Multidisciplinary Sciences

Stopping pandemics before they start: Lessons learned from SARS-CoV-2

Aled M. Edwards et al.

Summary: This article discusses the remarkable effectiveness of vaccine and drug responses to COVID-19, emphasizing the importance of long-term investment in technology and basic science. It also highlights the ongoing global pandemic and recommends proactive measures to prepare for, minimize the impact of, and prevent future pandemics.

SCIENCE (2022)

Add to Collection

Review Immunology

Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective

Manojit Bhattacharya et al.

Summary: This review focuses on the neutralizing antibodies currently under clinical trials, discussing their characteristics, advantages, and effectiveness against SARS-CoV-2. The review also provides an overview of the clinical trial phases and the antibodies targeting emerging variants.

VACCINES (2022)

Add to Collection

Article Medicine, Research & Experimental

Leveraging lessons learned from the COVID-19 pandemic for HIV

Thomas Calder et al.

Summary: The rapid development of COVID-19 vaccines has provided valuable lessons for the development of an HIV vaccine, emphasizing the importance of public-private partnerships, equitable inclusion, and continued investment in basic research.

COMMUNICATIONS MEDICINE (2022)

Add to Collection

Letter Virology

Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia

Maria Mazzitelli et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19

Yi Jiang et al.

Summary: COVID-19 caused by SARS-CoV-2 has become a global pandemic, with efforts focused on developing therapeutic interventions, such as the approved emergency use of the nucleotide analog remdesivir. Studies have revealed the mechanisms of RNA recognition by RdRp and inhibition by nucleotide inhibitors, providing insights for drug development targeting RdRp.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options

Obireddy Sreekanth Reddy et al.

Summary: The article provides an overview of the life cycle and transmission routes of SARS-CoV-2, discussing potential therapeutic effects of two drugs (remdesivir and favipiravir) against COVID-19 based on current data. This review can serve as a reference for future studies.

CHEMBIOCHEM (2021)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutics development for Ebola virus disease: A recent scenario

Chiranjib Chakraborty

Summary: Ebola virus disease is a deadly pathogenic disease caused by the Ebola virus, with scientists focusing on various therapeutic developments. Two monoclonal antibodies have shown efficacy in clinical trials and received approval, but there is a need for further development of more cost-effective therapies.

CURRENT OPINION IN PHARMACOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Goran Kokic et al.

Summary: Remdesivir is the only FDA-approved drug for treating COVID-19 patients, working by inhibiting the RNA-dependent RNA polymerase (RdRp) of coronaviruses. It hinders RNA synthesis and impairs proofreading by the viral 3'-exonuclease, leading to a stalled replication process.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Pharmacology & Pharmacy

SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development

Chiranjib Chakraborty et al.

Summary: This article explores the protein drug targets and drug discovery approaches for SARS-CoV-2, focusing on drug repurposing studies, design of viral entry inhibitors, and development of different enzymes. By conducting comprehensive literature searches, the structural landscape of viral and host proteins is illustrated, providing insights for understanding drug targets and structure-based drug discovery for SARS-CoV-2.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

Katerina Naydenova et al.

Summary: The structure of the RNA polymerase inhibitor favipiravir bound to the SARS-CoV-2 RNA-dependent RNA polymerase has been determined, revealing its binding mode at the catalytic site. The inhibitor is weakly incorporated into the RNA primer strand, leading to suppression of RNA replication in the presence of natural nucleotides.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Review Pharmacology & Pharmacy

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies

Chiranjib Chakraborty et al.

Summary: The rapid spread of SARS-CoV-2 globally has highlighted the need for effective treatment options. Drug repurposing of existing medications has become a key strategy in managing COVID-19 patients. Clinical trials conducted across multiple countries have shown promising results in antiviral and immunotherapeutic treatments, indicating the importance of further research in this area.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication

Jack P. K. Bravo et al.

Summary: Remdesivir, a nucleoside analog approved by the US FDA for treating COVID-19, was found to delay chain termination by blocking RNA translocation on RNA-dependent RNA polymerase, providing insights for rational design of improved antiviral drugs.

MOLECULAR CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination

Aditya K. Padhi et al.

Summary: Favipiravir is a broad-spectrum inhibitor of SARS-CoV-2 RdRp, but mutations in the RdRp may lead to resistance. By focusing on the chain-termination mechanism used by favipiravir, researchers identified potential mutational hotspots and single-point mutants that could confer resistance. This study improves our understanding of how SARS-CoV-2 may adapt against favipiravir.

FEBS LETTERS (2021)

Add to Collection

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Kimiyasu Shiraki et al.

PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Medicine, Research & Experimental

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More

Abinit Saha et al.

ARCHIVES OF MEDICAL RESEARCH (2020)

Add to Collection

Editorial Material Medicine, Research & Experimental

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19

Abinit Saha et al.

ARCHIVES OF MEDICAL RESEARCH (2020)

Add to Collection

Letter Infectious Diseases

Favipiravir, an antiviral for COVID-19?

Eric A. Coomes et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Wanchao Yin et al.

SCIENCE (2020)

Add to Collection

Editorial Material Virology

COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients

Chiranjib Chakraborty et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2 RNA polymerase as target for antiviral therapy

Luigi Buonaguro et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Microbiology

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

Rudra P. Saha et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Letter Critical Care Medicine

Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Dian Fu et al.

CRITICAL CARE (2020)

Add to Collection

Review Ophthalmology

COVID-19 pandemic: Lessons learned and future directions

Rohit C. Khanna et al.

INDIAN JOURNAL OF OPHTHALMOLOGY (2020)

Add to Collection

Review Public, Environmental & Occupational Health

Ebola virus disease: Recent advances in diagnostics and therapeutics

Supriya Jagga et al.

ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

PDBsum: Structural summaries of PDB entries

Roman A. Laskowski et al.

PROTEIN SCIENCE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update)

Lukas Pravda et al.

NUCLEIC ACIDS RESEARCH (2018)

Add to Collection

Letter Medicine, General & Internal

Mutagenesis in Norovirus in Response to Favipiravir Treatment

Christopher Ruis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

DynOmics: dynamics of structural proteome and beyond

Hongchun Li et al.

NUCLEIC ACIDS RESEARCH (2017)

Add to Collection

Review Multidisciplinary Sciences

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Yousuke Furuta et al.

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)

Add to Collection

Article Virology

T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug

T. Tanaka et al.

ACTA VIROLOGICA (2017)

Add to Collection

Article Microbiology

Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis

Evelien Vanderlinden et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Medicine, General & Internal

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Daouda Sissoko et al.

PLOS MEDICINE (2016)

Add to Collection

Article Infectious Diseases

Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus

V. Karthick et al.

INFECTIOUS DISEASES OF POVERTY (2016)

Add to Collection

Letter Medicine, General & Internal

Ebola eradication may need wider partnership

Govindasamy Agoramoorthy et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2014)

Add to Collection

Review Pharmacology & Pharmacy

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Yousuke Furuta et al.

ANTIVIRAL RESEARCH (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Favipiravir (T-705) inhibits in vitro norovirus replication

J. Rocha-Pereira et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)

Add to Collection

Article Chemistry, Medicinal

LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery

Roman A. Laskowski et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Computer-aided drug design platform using PyMOL

Markus A. Lill et al.

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2011)

Add to Collection

Article Multidisciplinary Sciences

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

Maki Kiso et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection

Article Microbiology

Efficacy of orally administered T-705 on lethal avian influenza a (H5N1) virus infections in mice

Robert W. Sidwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.